|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
<b>Conclusion:</b> MUC1 rs4072037 polymorphism is associated with decreased cancer risk and can probably be used as a tumor marker, especially for gastric cancer and for Asians.
|
30271495 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
<i>In vivo</i>, estrogen and ruxolitinib significantly reduced tumor size and decreased expression of MUC1, P-STAT1, and IFITM1.
|
30655323 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor cell MUC1 and CD43 are glycosylated differently with sialyl-Lewis a and x epitopes and show variable interactions with E-selectin under physiological flow conditions.
|
12820726 |
2003 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumors showed increased expression of MUC1 glycoprotein and triggered de novo antibodies in tumor bearing hosts, mimicking the immunobiology seen in patients.
|
25078979 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor-associated MUC1 is a promising antigen for the design of antitumor vaccines.
|
29345713 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor cell-endothelial adhesion is one of the key steps in tumor cell haematogenous dissemination in metastasis and was previously shown to be mediated by interaction of galectin-3 with the transmembrane mucin protein MUC1.
|
30171204 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor distance from the anal verge, acellular mucin pools, and MUC1 expression were associated with distant metastasis in patients with pCR.
|
30879932 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor markers such as carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) are widely used for monitoring breast cancer.
|
31312932 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor-associated MUC1 is expressed on over 90 % of all breast cancer entities and differs strongly from its physiological form on epithelial cells, therefore presenting a unique target for breast cancer diagnosis and antibody-mediated immune therapy.
|
31588183 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MUC1 expression was detected in 57.5% of the tumour samples, while TFF1 and MUC5AC were found in 10% and 7.5% of the cases respectively.
|
10190312 |
1999 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MUC1 was markedly overexpressed in the tumor at the mRNA and protein levels relative to lymphoma cell lines lacking a 1q21 rearrangement.
|
10753849 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MUC1 immunoreactivity of the surface was identical with that of the whole tumor in 81% (70/86) of carcinomas, MUC 2 in 87% and p53 in 100%.
|
10768872 |
2000 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MUC1 mucin expression has been shown to be associated clinicopathologically with metastasis and poor clinical outcome in a variety of tumors.
|
11058865 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MUC1 Ab-dependent cell-mediated tumor cell killing may occur in vivo and the ADCC assay can be applied to monitor MUC1 vaccination trials.
|
11391628 |
2001 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MUC1, MUC3 and MUC6 are expressed in normal and tumour kidney.
|
12010365 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MUC1 is associated with tumour aggressiveness in human breast cancer.
|
14534730 |
2004 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MUC1 is an oncoprotein whose overexpression correlates with aggressiveness of tumors and poor survival of cancer patients.
|
16846534 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MUC1 has generated considerable interest as a tumor marker and potential target for tumor killing.
|
17145869 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CA 15-3 is a widely used tumor marker for breast cancer.
|
19121298 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MUC1, a tumor associated glycoprotein over-expressed in 95% of pancreatic cancers, has been shown to be associated with a worse prognosis.
|
19482310 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MUC1 knockdown inhibited tumor growth and metastasis in an orthotopic mouse model of lung cancer by activating apoptosis and inhibiting cell proliferation in vivo.
|
19578748 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MUC1 is a useful molecular marker for malignant intraductal papillary mucinous neoplasms in pancreatic juice obtained from endoscopic retrograde pancreatography.
|
20357691 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mucin 1 (MUC1), a tumor-associated antigen, is a transmembrane glycoprotein expressed by normal epithelial cells and overexpressed by carcinomas of epithelial origin.
|
20876819 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MUC 1 and MUC 4 were expressed 4.2- and 21-fold higher in stage I disease in tumor tissue compared to normal, respectively.
|
21072847 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MUC1 was strongly expressed in normal gastric epithelium; however, the expression rate decreased with the loss of tumor differentiation (92.6% in well differentiated tumors, 83.7% in poorly differentiated tumors), with an increase in the number of metastatic lymph nodes (98.4% in tumors with no metastatic lymph nodes, 67.9% in tumors with lymph node metastasis-pN3), and with the progression in the tumor stage (100% in stage 1 tumors, 75.6% in stage 4 tumors).
|
21331986 |
2010 |